Danish pharmaceutical company Novo Nordisk B A/S (NOV.DE,NOVOB.CO,NVO) and German biomedical research institute BioMed X Tuesday announced a new collaboration to create effective oral delivery methods for therapeutic peptides. To tackle this issue, BioMed X and Novo Nordisk will establish a joint research team dedicated to advancing next-generation peptide formulations.
According to BioMed X, the project, titled "Prolonged Retention of Oral Peptide Formulations in the Gut", will be hosted at the company's Heidelberg campus. Its goal is to develop innovative oral formulation technologies capable of achieving site-specific, prolonged retention of tablets or capsules in the lower small intestine. The new research team will become part of the wider BioMed X research community in Heidelberg.
BioMed X said that current oral peptide formulations are limited by poor intestinal permeability and rapid gastrointestinal transit and such innovations would enable continuous drug release and efficient absorption while preserving gastrointestinal safety, and ultimately improving the patient's health.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.